Related Experiment Video
Updated: May 7, 2026
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Survival after left ventricular assist device with and without temporary right ventricular support
John F Lazar1, Michael F Swartz, Matthew P Schiralli
1Division of Cardiac Surgery, University of Rochester, Rochester, New York.
The Annals of Thoracic Surgery
|September 17, 2013
Summary
Biventricular support with a HeartMate II LVAD and CentriMag RVAD shows good short-term survival but lower 1-year survival compared to isolated LVAD support. This highlights challenges in long-term outcomes for complex heart failure patients.
Area of Science:
- Cardiology
- Mechanical Circulatory Support
Background:
- Right ventricular (RV) failure post-left ventricular assist device (LVAD) insertion is associated with poor outcomes.
- Patients needing temporary RV support after LVAD are a heterogeneous group.
- A hybrid system of HeartMate II LVAD and CentriMag RVAD is used for biventricular support.
Purpose of the Study:
- To determine 1-year survival in patients receiving isolated LVAD versus biventricular support.
Main Methods:
- Analysis of patients undergoing HeartMate II LVAD implantation alone or with CentriMag RVAD from 2006-2011.
- Evaluation of preoperative demographics, operative outcomes, and survival data.
Main Results:
- 34% of 139 patients required biventricular support.
- RVAD support duration averaged 17 days, with 91.8% successful explantation.
- Hospital discharge survival was similar, but 1-year survival was significantly higher for isolated LVAD (87%) vs. biventricular support (77%).
Conclusions:
- Biventricular support with HeartMate II LVAD and CentriMag RVAD offers acceptable hospital discharge survival.
- Biventricular dysfunction requiring temporary RVAD support is associated with less favorable 1-year outcomes compared to isolated LVAD support.
Keywords:
27
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.